DERMATOLOGICAL SIDE EFFECTS OF CURRENT AND UPCOMING TARGETED THERAPIES IN ONCOLOGY

被引：7

作者：

Bonny, M. ^{[1
]}

Buyse, V ^{[2
]}

Brochez, L. ^{[1
]}

机构：

[1] Univ Hosp Ghent, Dept Dermatol, Ghent, Belgium

[2] OLV van Lourdes Hosp, Waregem, Belgium

来源：

ACTA CLINICA BELGICA | 2011年 / 66卷 / 02期

关键词：

Skin toxicity; targeted therapy; oncology; ORAL MEK INHIBITOR; RENAL-TRANSPLANT RECIPIENTS; PHASE-I; ADVANCED CANCERS; CELL LUNG; BEVACIZUMAB; MANAGEMENT; SIROLIMUS; ERUPTION; PD-0325901;

D O I：

10.2143/ACB.66.2.2062526

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Targeted therapies are gaining field in oncology practice. Some of them are already well established, others are upcoming. They target cancer cells more selectively, therefore causing less collateral damage. Dermatologic side effects are common and sometimes class specific. The skin toxicity profile of EGFR inhibitors, MEK en Raf inhibitors, mTOR inhibitors, VEGF targeting molecules, multikinase inhibitors, the HER2 monoclonal antibody trastuzumab and the CTLA-4 monoclonal antibodies are discussed. When possible, a pathogenic mechanism and treatment options are described.

引用

页码：97 / 103

页数：7

共 39 条

[1]

Abe Hajime, 2010, Gan To Kagaku Ryoho, V37, P1887

[2] Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers [J].

Adjei, Alex A. ;

Cohen, Roger B. ;

Franklin, Wilbur ;

Morris, Clive ;

Wilson, David ;

Molina, Julian R. ;

Hanson, Lorelei J. ;

Gore, Lia ;

Chow, Laura ;

Leong, Stephen ;

Maloney, Lara ;

Gordon, Gilad ;

Simmons, Heidi ;

Marlow, Allison ;

Litwiler, Kevin ;

Brown, Suzy ;

Poch, Gregory ;

Kane, Katie ;

Haney, Jerry ;

Eckhardt, S. Gail .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (13) :2139-2146

[3] Papulopustular eruption after intravitreal bevacizumab (Avastin®) [J].

Amselem, Luis ;

Diaz-Llopis, Manuel ;

Garcia-Delpech, Salvador ;

Montero, Javier ;

Palomares, Paula ;

Cervera, Enrique .

ACTA OPHTHALMOLOGICA, 2009, 87 (01) :110-111

[4]

Balagula V, INVEST NEW DRUGS

[5]

Blay J-Y, 2010, ANN ONCOL 0629

[6] mTOR inhibitor-associated dermatologic and mucosal problems [J].

Campistol, Josep M. ;

de Fijter, Johan W. ;

Flechner, Stuart M. ;

Langone, Anthony ;

Morelon, Emmanuel ;

Stockfleth, Eggert .

CLINICAL TRANSPLANTATION, 2010, 24 (02) :149-156

[7] Sirolimus-associated lymphoedema: eight new cases and a proposed mechanism [J].

Desai, N. ;

Heenan, S. ;

Mortimer, P. S. .

BRITISH JOURNAL OF DERMATOLOGY, 2009, 160 (06) :1322-1326

[8] Case studies showing clinical signs and management of cutaneous toxicity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with solid tumours [J].

Desar, Ingrid M. E. ;

Bovenschen, H. Jorn ;

Timmer-Bonte, Anja J. N. H. ;

Cantarini, Mireille V. ;

van der Graaf, Winette T. A. ;

van Rossum, Michelle M. ;

van Herpen, Carla M. L. .

ACTA ONCOLOGICA, 2010, 49 (01) :113-116

[9]

Dick S.E., 2005, Community Oncology, V2, P492

[10] Inhibition of Mutated, Activated BRAF in Metastatic Melanoma [J].

Flaherty, Keith T. ;

Puzanov, Igor ;

Kim, Kevin B. ;

Ribas, Antoni ;

McArthur, Grant A. ;

Sosman, Jeffrey A. ;

O'Dwyer, Peter J. ;

Lee, Richard J. ;

Grippo, Joseph F. ;

Nolop, Keith ;

Chapman, Paul B. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (09) :809-819

← 1 2 3 4 →